Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome
- 19 March 2020
- journal article
- research article
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 25 (3) , 176-181
Abstract
Objectives: The aim of the study was to update the results of a previous study published 10 years ago and compare the effect on hyperandrogenism of a newer progestin, dienogest (DNG), in a combined oral contraceptive (COC) formulation with ethinylestradiol (EE), with that of COCs containing the same dose of EE in combination with drospirenone (DRSP) and chlormadinone acetate (CMA). Methods: Sixty women with polycystic ovary syndrome (PCOS) aged between 16 and 35 and requiring antiandrogenic contraceptive treatment were randomised to one of three treatment groups: EE 30 µg/DRSP 3 mg, EE 30 µg/CMA 2 mg, EE 30 µg/DNG 2 mg. We evaluated the effects of the three COCs on sex hormone-binding globulin (SHBG) and biochemical markers of hyperandrogenism. Results: After 3 months of treatment, serum androgen concentrations were significantly improved in all treatment groups. Serum concentrations of SHBG were significantly increased with all COC treatments (p < 0.0001). Interestingly, DRSP had a greater effect (+218%; p < 0.0001) on serum SHBG concentrations compared with DNG and CMA (p < 0.04 and p < 0.002, respectively). Serum concentrations of total testosterone significantly decreased in all groups (p < 0.0001). DRSP had a significantly greater effect on total testosterone concentrations compared with DNG (p = 0.002) and CMA (p < 0.0001). Conclusion: Our study showed that DNG exerted an important stimulatory effect on SHBG concentrations, which was less than that of DRSP but greater than that of CMA. Similar results were also obtained for dehydroepiandrosterone sulphate and total testosterone.Keywords
This publication has 31 references indexed in Scilit:
- Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-AnalysisJMIR Research Protocols, 2018
- Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestinsMetabolism, 2017
- Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefitsOpen Access Journal of Contraception, 2017
- Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and ManagementCurrent Pharmaceutical Design, 2016
- Genetic, hormonal and metabolic aspects of PCOS: an updateReproductive Biology and Endocrinology, 2016
- The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndromeAtherosclerosis, 2008
- Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndromeFertility and Sterility, 2007
- Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesisHuman Reproduction, 2006
- Progestogens with Antiandrogenic PropertiesDrugs, 2003
- Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndromeHuman Reproduction, 2001